证券代码：002901 证券简称：大博医疗 公告编号：2025-036 大博医疗科技股份有限公司 监事会关于授予预留股票期权的激励对象名单的核查意见 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）监事会根据《公司法》《证 券法》《上市公司股权激励管理办法》（以下简称"《管理办法》"）等有关法律、 法规和规范性文件以及公司《2024 年股票期权激励计划（草案）》和《公司章程》 的有关规定，对公司本次授予预留股票期权的激励对象名单进行核实并发表意见 如下： （一）监事会就授予条件是否成就发表的明确意见 （1）公司不存在《上市公司股权激励管理办法》等规定的禁止实施股权激 励计划的情形，公司具备实施股权激励计划的主体资格。 （2）公司 2024 年股票期权激励计划预留股票期权授予激励对象符合《公司 法》《证券法》《公司章程》规定的任职资格，不存在《上市公司股权激励管理办 法》规定的禁止成为激励对象的情形，符合《上市公司股权激励管理办法》等适 用法律规定的激励对象条件以及本次股票期权激励计划规定的激励对象范围，该 等激励对象 ...

证券代码：002901 证券简称：大博医疗 公告编号：2025-038 本次会议由监事会主席詹欢欢女士主持，与会监事就会议议案进行了审议、 表决，形成了如下决议： 大博医疗科技股份有限公司 一、会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于调 整 2024 年股票期权激励计划行权价格的议案》。 经审核，监事会认为：公司本次调整行权价格符合《上市公司股权激励管理 办法》《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》及公司 《2024 年股票期权激励计划》等相关规定，调整程序合法、有效。同意对股票 期权的行权价格进行调整，本次调整后，2024 年股票期权激励计划的行权价格 由 23.89 元/股调整为 23.39 元/股。 具体内容详见 2025 年 9 月 18 日刊登在指定信息披露媒体及巨潮资讯网 （www.cninfo.com.cn）上的《关于调整 2024 年股票期权激励计划行权价格的公 告》。 二、会议以 3 票同意、0 票反对、0 票弃权的表决结果审议通过《关于向激 1 第三届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 ...

Group 1 - The core point of the article is that Dabo Medical (SZ 002901) announced the convening of its 19th meeting of the third board of directors on September 17, 2025, to review the proposal for adjusting the exercise price of the 2024 stock option incentive plan [1] - For the first half of 2025, Dabo Medical's revenue composition is entirely from the medical device manufacturing industry, accounting for 100.0% [1] - As of the time of reporting, Dabo Medical has a market capitalization of 22.6 billion yuan [1]

证券代码：002901 证券简称：大博医疗 公告编号：2025-037 大博医疗科技股份有限公司 第三届董事会第十九次会议决议公告 本议案提交董事会前已经公司董事会薪酬与考核委员会 2025 年第二次会议 审议通过，律师就本议案发表了同意结论的意见。 董事罗炯为 2024 年股票期权激励计划的激励对象，对该议案回避表决。 具体内容详见 2025 年 9 月 18 日刊登在指定信息披露媒体及巨潮资讯网 （www.cninfo.com.cn）上的《关于调整 2024 年股票期权激励计划行权价格的公 告》及《关于大博医疗科技股份有限公司 2024 年股票期权激励计划预留授予及 调整行权价格事项的法律意见书》。 二、会议以 7 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于向 激励对象授予预留股票期权的议案》。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届董事会第十九次会 议于2025年9月17日在公司会议室以现场及通讯相结合方式召开，会议通知以专 人送达、传真、电子邮件、电话相结合的方式已于2025年9 ...

Core Viewpoint - The stock of Dabo Medical (002901) has shown a slight increase in price, with significant net inflows from retail investors despite overall net outflows from institutional and speculative funds [1][2]. Financial Performance - Dabo Medical reported a total revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year increase of 25.55% [3] - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3] - The company's gross profit margin stands at 71.01%, significantly higher than the industry average of 51.85% [3] - The second quarter of 2025 saw a single-quarter revenue of 660 million yuan, a 22.96% increase year-on-year, with a net profit of 141 million yuan, reflecting an 84.47% increase [3] Market Position - Dabo Medical's total market capitalization is 23.119 billion yuan, ranking 10th in the medical device industry [3] - The company has a price-to-earnings ratio of 47.32, which is lower than the industry average of 67.38, indicating a relatively favorable valuation [3] - The return on equity (ROE) is 7.6%, significantly higher than the industry average of 1.8%, showcasing effective management of equity [3] Fund Flow Analysis - On September 11, 2025, the stock experienced a net outflow of 29.5822 million yuan from institutional investors, accounting for 14.33% of the total trading volume [1][2] - Retail investors contributed a net inflow of 34.4472 million yuan, representing 16.69% of the total trading volume on the same day [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with notable retail investor activity during periods of price decline [2]

证券之星消息，截至2025年9月10日收盘，大博医疗(002901)报收于55.74元，上涨0.02%，换手率 0.98%，成交量2.84万手，成交额1.58亿元。 9月10日的资金流向数据方面，主力资金净流出551.75万元，占总成交额3.48%，游资资金净流入391.93 万元，占总成交额2.47%，散户资金净流入159.82万元，占总成交额1.01%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-10 | 55.74 0.02% | | -551.75万 | -3.48% | 391.93万 | 2.47% | 159.82万 | liv 1.01% | | 2025-09-09 | 55.73 -4.31% | | ● 901.60万 | 3.32% | 676.73万 | 2.49% | -1578.32万 | -5.82% | | 2025-09-08 | 58. ...

从大博医疗十大流通股东角度 9月9日，大博医疗跌5.05%，截至发稿，报55.30元/股，成交2.52亿元，换手率1.54%，总市值228.95亿 元。 资料显示，大博医疗科技股份有限公司位于福建省厦门市海沧区山边洪东路18号，成立日期2004年8月 12日，上市日期2017年9月22日，公司主营业务涉及医用高值耗材的生产、研发与销售。主营业务收入 构成为：创伤类产品38.68%，脊柱类产品17.95%，微创外科类产品16.34%，关节类产品10.37%，其他 产品9.27%，神经外科类产品4.50%，齿科类产品2.89%。 数据显示，南方基金旗下1只基金位居大博医疗十大流通股东。南方中证1000ETF（512100）二季度增 持14.19万股，持有股数75.68万股，占流通股的比例为0.26%。根据测算，今日浮亏损失约222.49万元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿， ...

Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]

Group 1 - The medical device sector experienced a significant upward movement on September 8, with companies such as Aojing Medical, United Imaging Medical, and Kaili Medical seeing stock increases of over 10% [1] - Other companies in the sector, including Jimin Health, BGI Genomics, Dabo Medical, and Mindray Medical, also showed positive stock performance [1]

Core Viewpoint - Dabo Medical (002901) shows a positive performance with a closing price of 54.39 yuan, up 1.76% as of September 5, 2025, despite some net outflows from major and retail investors [1] Financial Performance - Dabo Medical reported a main revenue of 1.21 billion yuan for the first half of 2025, an increase of 25.55% year-on-year [3] - The net profit attributable to shareholders reached 244 million yuan, up 76.69% year-on-year [3] - The net profit excluding non-recurring items was 223 million yuan, reflecting an increase of 82.64% year-on-year [3] - In Q2 2025, the company achieved a single-quarter main revenue of 660 million yuan, up 22.96% year-on-year [3] - The single-quarter net profit attributable to shareholders was 141 million yuan, up 84.47% year-on-year [3] - The single-quarter net profit excluding non-recurring items was 126 million yuan, up 73.04% year-on-year [3] Market Position - Dabo Medical's total market capitalization is 22.519 billion yuan, ranking 11th in the medical device industry [3] - The company's net assets stand at 3.233 billion yuan, ranking 45th in the industry [3] - The net profit margin is 21.42%, ranking 33rd in the industry [3] - The company has a gross margin of 71.01%, significantly higher than the industry average of 51.85% [3] - The price-to-earnings ratio (P/E) is 46.1, which is lower than the industry average of 65.4 [3] Investor Sentiment - As of the last 90 days, one institution has given a buy rating for Dabo Medical [4]